Edition:
United Kingdom

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

83.16USD
9:00pm BST
Change (% chg)

$-0.65 (-0.78%)
Prev Close
$83.81
Open
$84.11
Day's High
$84.23
Day's Low
$82.90
Volume
988,198
Avg. Vol
1,534,805
52-wk High
$85.99
52-wk Low
$61.56

Select another date:
Photo

Abbott to hike production of lower-cost glucose monitors as diabetes soars

CHICAGO Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters.

Abbott to hike production of lower-cost glucose monitors as diabetes soars

CHICAGO Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters.

FOCUS- Abbott to hike production of lower-cost glucose monitors as diabetes soars

CHICAGO, July 16 Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters.

Abbott device helps in cutting blood sugar in type 2 diabetics: study

Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday.

CORRECTED-Abbott device helps in cutting blood sugar in type 2 diabetics - study (June 8)

June 8 Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday.

Abbott Labs quarterly beat overshadowed by unchanged forecast

Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge.

UPDATE 2-Abbott Labs quarterly beat overshadowed by unchanged forecast

April 17 Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge.

Abbott Lab's first-quarter sales beat expectations

April 17 Abbott Laboratories Inc reported first-quarter sales ahead of Wall Street expectations on Wednesday, on double digit growth of its Freestyle Libre glucose monitoring device and as more of its heart valves were used in surgical procedures.

Abbott misses revenue estimates, sees lackluster first-quarter profit

Abbott Laboratories missed analysts' estimates for fourth-quarter revenue on Wednesday due to lower sales of its generic drugs in emerging markets as well as a strong dollar, and also forecast current-quarter profit below expectations.

UPDATE 3-Abbott misses revenue estimates, sees lackluster first-qtr profit

Jan 23 Abbott Laboratories missed analysts' estimates for fourth-quarter revenue on Wednesday due to lower sales of its generic drugs in emerging markets as well as a strong dollar, and also forecast current-quarter profit below expectations.

Select another date: